Screening and treatment methods using IGS5 enzymes of the metalloprotease family
AssigneeAbbott Healthcare Products B.V.
InventorsWilly Deleersnijder, Yasmin Karimi-Nejad, Michael Weske, Dieter Ziegler
Life of this patent
Estimating the term…
Loading patent…
AssigneeAbbott Healthcare Products B.V.
InventorsWilly Deleersnijder, Yasmin Karimi-Nejad, Michael Weske, Dieter Ziegler
Estimating the term…
Polypeptides which are related to the neprilysin enzyme family and have zinc metalloprotease activities and are referred to as IGS5, polynucleotides encoding such polypeptides, vectors containing such polynucleotides, host cells containing such vectors, processes for producing such polypeptides and/or polynucleotides, screening methods for identifying compounds which stimulate or inhibit IGS5 polypeptides and/or polynucleotides, and the use of such polypeptides and/or polynucleotides in therapy of various dysfunctions, disorders or diseases, particularly cardiovascular diseases, metabolic diseases such as diabetes mellitus type II, and neurodegenerative disorders, such as Parkinson's Disease.
A method for the treatment of a neurodegenerative disease in a mammalian subject, the method comprising the step of administering to said subject an effective amount of a compound inhibiting or decreasing activity of an neprilysin II (IGS5) polypeptide wherein said IGS5 polypeptide has a zinc metallopeptidase activity and comprises a human amino acid sequence having at least 95% sequence identity to SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6 and wherein said compound is selected from the group consisting of:
Dependencies are inferred from the claim text.